Quotes 5-day view Delayed Japan Exchange
01/27/2023
01/30/2023
01/31/2023
02/01/2023
02/02/2023
Date
3444(c)
3392(c)
3358(c)
3325(c)
3296
Last
1 726 100
1 919 400
1 731 900
2 220 000
2 377 400
Volume
-1.20%
-1.51%
-1.00%
-0.98%
-0.87%
Change
Estimated financial data (e) JPY USD
Sales 2022
1 197 B
9 254 M
9 254 M
Net income 2022
352 B
2 721 M
2 721 M
Net cash position 2022
532 B
4 115 M
4 115 M
P/E ratio 2022
15,5x
Yield 2022
2,39%
Sales 2023
1 041 B
8 051 M
8 051 M
Net income 2023
313 B
2 417 M
2 417 M
Net cash position 2023
753 B
5 825 M
5 825 M
P/E ratio 2023
17,5x
Yield 2023
2,52%
Capitalization
5 470 B
42 302 M
42 302 M
EV / Sales 2022
4,13x
EV / Sales 2023
4,53x
Nbr of Employees
7 664
Free-Float
38,0%
Chugai Pharmaceutical Co. Ltd specializes in the research, development, manufacturing and marketing of drugs especially for cancers (40.8% of net sales), bones and joints diseases treatment (18.4%), and kidney diseases (5.9%).
Net sales are distributed geographically as follows: Japan (74,3%), Switzerland (22,8%) and other (2,9%).
Ratings of Chugai Pharmaceutical Co., Ltd
All news about CHUGAI PHARMACEUTICAL CO., LTD
News in other languages on CHUGAI PHARMACEUTICAL CO., LTD
ETFs positioned on CHUGAI PHARMACEUTICAL CO., LTD ETFs and Trackers with Trackinsight
Chart CHUGAI PHARMACEUTICAL CO., LTD
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends CHUGAI PHARMACEUTICAL CO., LTD
Short Term Mid-Term Long Term Trends Neutral Bearish Bearish
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
OUTPERFORM
Number of Analysts
13
Last Close Price
3 325,00 JPY
Average target price
4 339,23 JPY
Spread / Average Target
30,5%
Please enable JavaScript in your browser's settings to use dynamic charts.